eCyte Launched Digital Colony Picker for Biotech
The new device automates clone identification and recovery to bypass traditional laboratory limitations.
Updated on Sept. 21, 2026 in Life Sciences
Live Poll
Is now a good time for laboratories to transition to automated microfluidic screening platforms?
eCyte has released the Digital Colony Picker, a platform that utilizes microchamber technology to isolate and analyze biological colonies. The instrument aims to solve common bottlenecks in cell screening where fast-growing organisms typically outcompete and mask low-abundance, high-value variants.
Why it matters
Conventional agar plate methods often fail to capture diverse cell populations because dominant strains crowd out others during incubation. This device allows researchers to maintain individual cell integrity, significantly improving the yield of rare, high-performance biological variants.
The system utilizes a Static Droplet Array chip featuring 16,000 picoliter-scale microchambers that allow for high-throughput analysis. An AI-guided pipeline evaluates these chambers at a rate of 800 per minute using 470 nm and 530 nm excitation wavelengths.
The players
eCyte
This biotechnology company focuses on developing high-throughput automated systems for cellular screening and clone recovery.
Diao et al.
This research group published a 2025 validation study in Nature Communications demonstrating the device's efficacy in identifying high-growth variants.
The details
By using vacuum-assisted loading, cell suspensions are distributed into individual microchambers, enabling contactless optical recovery of up to 5,000 clones per chip. This process effectively replaces 50 traditional agar plates in a single screening run, allowing for precise control over the identification of specific biological traits.
Timeline
Diao et al. validated the device in 2025.
eCyte raised a Series A Extension in January 2026.
The Digital Colony Picker was released in September 2026.
The Big Picture
This innovation follows the validation framework established by the 2025 Nature Communications study by Diao et al. It marks a shift from manual plate-based screening toward automated, chip-based isolation that effectively bridges the gap between basic laboratory research and industrial cell line development.
Researchers can utilize this technology to significantly reduce the time and material costs associated with identifying high-producing cell lines. These efficiencies could accelerate the development of future biopharmaceuticals and high-yield agricultural products.
The takeaway
The platform represents a major technological leap for labs moving away from error-prone agar plate incubation methods. Scientists should consider how high-throughput, AI-guided identification could streamline their own metabolic or genetic screening pipelines.
Further reading
For more information on similar developments in the field, visit Life Sciences.
Source note: This article includes information reported by Lab Manager.
Live Poll
Is now a good time for laboratories to transition to automated microfluidic screening platforms?
